Audit Report Correction: Prior Year Opinion Revised to Qualified, Internal Control Adverse


  • Audit report correction: prior fiscal year (2023) audit opinion changed from 'unqualified' to 'qualified due to scope limitation'
  • Internal accounting control system audit opinion: both current (2024) and prior year marked as 'adverse'
  • Current year (2024) audit opinion is 'unqualified' but internal control is adverse
  • Going concern uncertainty: not applicable for both years
  • Embezzlement/fraud matters noted in audit report (Yes)
  • Financials (2024): assets 140.7B won, liabilities 96.7B won, equity 44.0B won (no capital impairment)
  • P&L (2024): revenue 88.4B won, operating loss 5.7B won, net loss 14.6B won (loss widened from prior year net loss of 6.0B won)
  • Auditor: Hanul LLC
ADVERTISEMENT (250px+)

KOSPI Filing Information


  • Filing: [Correction of Description] Audit Report Submission
  • Company: Dongsung Pharmaceutical (002210)
  • Submission: Dongsung Pharmaceutical Co., Ltd.
  • Receipt: 04-30-2026
  • Under KRX KOSPI Market Division